Nivolumab in NSCLC: latest evidence and clinical potential.

  title={Nivolumab in NSCLC: latest evidence and clinical potential.},
  author={Raghav Sundar and Byoung-Chul Cho and Julie Renee Brahmer and Ross A. Soo},
  journal={Therapeutic advances in medical oncology},
  volume={7 2},
New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 51 extracted citations

Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity?

Clinical oncology (Royal College of Radiologists (Great Britain)) • 2017

Similar Papers

Loading similar papers…